Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19.
COVID-19 Drug Treatment , Depsipeptides/therapeutic use , Hospitalization/statistics & numerical data , Peptides, Cyclic/therapeutic use , SARS-CoV-2/drug effects , Adult , Aged , COVID-19/virology , Cell Line, Tumor , Depsipeptides/adverse effects , Depsipeptides/pharmacology , Drug Evaluation, Preclinical/methods , Female , Humans , Kaplan-Meier Estimate , Length of Stay/statistics & numerical data , Male , Middle Aged , Neutropenia/chemically induced , Peptides, Cyclic/adverse effects , Peptides, Cyclic/pharmacology , SARS-CoV-2/physiology , Treatment Outcome , Viral Load/drug effects
Fundamento y objetivo: Describir un cuadro clínico poco habitual como la tuberculosis esplénica aislada. Paciente y método: Presentamos un caso de tuberculosis esplénica aislada, una forma rara de tuberculosis extrapulmonar, en un paciente inmunocompetente, y que, como peculiaridad, comienza en forma de hipercalcemia sintomática. Resultados: Se expone ampliamente el caso clínico y los procedimientos realizados para excluir las patologías que integraron el diagnóstico diferencial. Hacemos énfasis en la utilidad de la punción aspirativa con aguja fina del bazo para la obtención de muestras microbiológicas, y el uso de la reacción en cadena de la polimerasa específica para micobacterias para confirmar el diagnóstico de esta entidad. Igualmente, de acuerdo con otros autores, optamos por un tratamiento médico inicial con antituberculostáticos, reservando la cirugía para los casos refractarios o que se compliquen con rotura esplénica espontánea. Conclusión: La hipercalcemia puede ser una forma de presentación de las enfermedades granulomatosas. La afectación aislada del bazo por micobacterias es una forma poco frecuente de tuberculosis extrapulmonar y más aún en pacientes inmunocompetentes (AU)
Background and objective: To describe an unusual clinical presentation as isolated splenic tuberculosis. Patient and methods: We report a case of isolated splenic tuberculosis, a rare form of extrapulmonary tuberculosis in an immunocompetent patient, and, as a peculiarity, debuts in the form of symptomatic hypercalcemia. Results: We deeply report the clinical case and the procedures performed to exclude other diseases. We emphasize the usefulness of fine needle aspiration of the spleen to obtain microbiological samples, and the use of specific polymerase chain reaction for mycobacterias to establish the definitive diagnosis of this entity. In agreement with other authors, we chose initial medical treatment with antituberculous drugs, reserving surgery for refractory cases or in case of spontaneous splenic rupture. Conclusion: Hypercalcemia can be a presentation of granulomatous diseases. The isolated involvement of the spleen by mycobacterias is a rare form of extrapulmonary tuberculosis and more so in immunocompetent patients (AU)
Humans , Male , Aged , Tuberculosis, Splenic/diagnosis , Hypercalcemia/etiology , Biopsy, Fine-Needle/methods , Polymerase Chain Reaction
BACKGROUND AND OBJECTIVE: To describe an unusual clinical presentation as isolated splenic tuberculosis. PATIENT AND METHODS: We report a case of isolated splenic tuberculosis, a rare form of extrapulmonary tuberculosis in an immunocompetent patient, and, as a peculiarity, debuts in the form of symptomatic hypercalcemia. RESULTS: We deeply report the clinical case and the procedures performed to exclude other diseases. We emphasize the usefulness of fine needle aspiration of the spleen to obtain microbiological samples, and the use of specific polymerase chain reaction for mycobacterias to establish the definitive diagnosis of this entity. In agreement with other authors, we chose initial medical treatment with antituberculous drugs, reserving surgery for refractory cases or in case of spontaneous splenic rupture. CONCLUSION: Hypercalcemia can be a presentation of granulomatous diseases. The isolated involvement of the spleen by mycobacterias is a rare form of extrapulmonary tuberculosis and more so in immunocompetent patients.
Hypercalcemia/etiology , Tuberculosis, Splenic/diagnosis , Aged , Humans , Male , Tuberculosis, Splenic/complications
Acidosis/chemically induced , Anticonvulsants/adverse effects , Epilepsies, Partial/drug therapy , Fructose/analogs & derivatives , Acidosis, Renal Tubular/chemically induced , Aged , Anticonvulsants/therapeutic use , Cerebral Hemorrhage, Traumatic/complications , Comorbidity , Drug Substitution , Epilepsies, Partial/etiology , Fructose/adverse effects , Fructose/therapeutic use , Humans , Male , Phenytoin/therapeutic use , Polypharmacy , Schizophrenia, Paranoid/drug therapy , Schizophrenia, Paranoid/etiology , Topiramate
Aspergillosis/diagnosis , Aspergillus fumigatus/isolation & purification , Liver Cirrhosis/complications , Lumbar Vertebrae/microbiology , Opportunistic Infections/diagnosis , Spondylitis/diagnosis , Antifungal Agents/therapeutic use , Aspergillosis/blood , Aspergillosis/complications , Aspergillosis/drug therapy , Aspergillosis/microbiology , Biomarkers , Cross Infection/complications , Cross Infection/microbiology , Fatal Outcome , Galactose/analogs & derivatives , Haemophilus influenzae , Hepatitis C, Chronic/complications , Humans , Immunocompromised Host , Low Back Pain/etiology , Male , Mannans/blood , Middle Aged , Multiple Organ Failure/etiology , Opportunistic Infections/blood , Opportunistic Infections/complications , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Pulmonary Disease, Chronic Obstructive/complications , Pyrimidines/therapeutic use , Spondylitis/blood , Spondylitis/complications , Spondylitis/drug therapy , Spondylitis/microbiology , Triazoles/therapeutic use , Voriconazole
Acetamides/adverse effects , Acidosis, Lactic/chemically induced , Anti-Bacterial Agents/adverse effects , Oxazolidinones/adverse effects , Acetamides/therapeutic use , Acidosis, Lactic/complications , Acidosis, Lactic/diagnosis , Aged , Anti-Bacterial Agents/therapeutic use , Comorbidity , Dyspnea/etiology , Endocarditis, Bacterial/drug therapy , Enterococcus faecalis , Gram-Positive Bacterial Infections/drug therapy , Humans , Linezolid , Male , Oxazolidinones/therapeutic use